NCT06513104

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

Investigation of the Effect of NNC0519-0130 on the Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Healthy Postmenopausal Females

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Female
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel. The study will also look into if NNC0519-0130 affects how fast stomach is emptied. Participants will get the new study medicine NNC0519-0130 and will also get birth control pills and paracetamol. The study will last for about 35 weeks.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	NNC0519-0130	NNC0519-0130 will be administered subcutaneously.
DRUG	Levonorgestrel + Ethinylestradiol	Levonorgestrel + Ethinylestradiol will be administered orally.
DRUG	Paracetamol	Paracetamol will be administered orally.

Timeline

• Start date: 2024-07-18
• Primary completion: 2025-09-10
• Completion: 2025-09-30
• First posted: 2024-07-22
• Last updated: 2026-03-12

Locations

1 site across 1 country: Germany